NCT00559975 - Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Study Completion Date

May 31, 2008

Conditions

Influenza Infection

Interventions

BIOLOGICAL

Subunit influenza vaccine

0.5 mL single dose vaccine

BIOLOGICAL

Adjuvanted influenza vaccine

0.5 mL single dose vaccine

BIOLOGICAL

Adjuvanted influenza vaccine combined with CpG7909

0.5 ml influenza vaccine combined with 10 mcg of CpG7909

BIOLOGICAL

Adjuvanted influenza vaccine combine with CpG7909

0.5 mL single dose vaccine combined with 30 mcg of CpG7909

BIOLOGICAL

Adjuvanted influenza vaccine combine with CpG7909

0.5 mL single dose vaccine combined with 100 mcg of CpG7909

Trial Locations (1)

Institute for Pharmacokinetic and Analytical Studies, Ligornetto